What are the best treatments for Fibromuscular dysplasia?

Treatment for Fibromuscular dysplasia (FMD) is highly individualized, focusing on managing hypertension and preventing complications like stroke or dissection rather than curing the underlying structural arterial changes. Current standards of care for Fibromuscular dysplasia prioritize blood pressure control through anti-hypertensive medications and, in select cases, revascularization procedures such as angioplasty to restore blood flow.

How is Fibromuscular dysplasia treated medically?

The primary goal in managing Fibromuscular dysplasia is the optimization of blood pressure to reduce the risk of arterial damage. Because FMD frequently affects the renal arteries, physicians often prescribe medications that block the renin-angiotensin-aldosterone system. Common medications include ACE inhibitors, such as lisinopril (Prinivil, Zestril), or angiotensin II receptor blockers (ARBs) like losartan (Cozaar). Additionally, many patients with Fibromuscular dysplasia are placed on antiplatelet therapy, such as low-dose aspirin, to reduce the risk of thromboembolic events. It is vital to note that treatment must be personalized by your medical team based on the specific arteries involved and your individual risk profile.

When is surgery or interventional procedure necessary for Fibromuscular dysplasia?

Revascularization is not required for all patients with Fibromuscular dysplasia. It is generally reserved for patients with uncontrolled hypertension, evidence of end-organ damage, or symptomatic ischemia (such as TIA or stroke). The most common procedure is percutaneous transluminal angioplasty (PTA), which involves inflating a balloon within the narrowed artery to improve blood flow. Unlike many other vascular conditions, stenting is rarely performed in FMD patients unless there is a complication like a flow-limiting dissection that does not respond to angioplasty alone.

Which specialists should be on my care team?

Managing Fibromuscular dysplasia requires a multidisciplinary approach to address the systemic nature of the condition. Your care team should ideally include:

• Vascular Medicine Specialists or Vascular Surgeons: To monitor arterial health and determine the need for interventions.


• Nephrologists: Essential for patients with renal artery involvement to manage blood pressure and kidney function.


• Neurologists or Neurosurgeons: Crucial for patients with carotid or vertebral artery involvement to monitor for signs of dissection or aneurysm.


• Clinical Geneticists: To provide counseling, as there is an increasing understanding of the genetic components involved in FMD development.

How does the experience of Fibromuscular dysplasia vary between patients?

The clinical presentation of Fibromuscular dysplasia is highly heterogeneous. Some individuals may remain asymptomatic for years, while others experience severe hypertension or vascular events early in life. Data from the 132 members within the DiseaseMaps community reflect this diversity, highlighting that while some patients find success with medication alone, others require repeated interventions. Effectiveness of treatment also varies based on the "type" of FMD (multifocal vs. focal) and the specific vascular beds affected.

Next steps

• Consult with a vascular specialist experienced specifically in Fibromuscular dysplasia, as this is a rare condition that requires expert nuance.


• Keep a detailed log of your blood pressure readings to share with your healthcare provider during follow-up visits.


• Connect with the DiseaseMaps community to share experiences and learn from others living with this diagnosis.


• Stay informed about current clinical trials via the NIH or FMD Society to see if you are a candidate for emerging research.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your physician for personalized treatment plans.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Fibromuscular dysplasia.


• Orphanet: Portal for rare diseases and orphan drugs (ORPHA:333).


• The FMD Society: Patient resources and physician directory.


• Journal of the American College of Cardiology: "Fibromuscular Dysplasia: State-of-the-Art Review."